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Background: Clobazam is used for the treatment of different types of seizure and epilepsy. The present research is
undertaken to study the systematic forced degradation of clobazam and to identify its main degradation product
under basic conditions.
Methods: The degradation of clobazam was studied under different conditions. Clobazam and its degradation
products were separated using a Nova-Pak C18 column and a mixture of KH2PO4 50 mM (pH 8.5) and acetonitrile
(50:50, v/v) as the mobile phase with UV detection at 230 nm.
Results: The within-day and between-day precision values in the calibration range of 0.1-20 μg/ml were within
0.5-1.5%. Clobazam was relatively stable in solid from under exposure to visible and UV light and also heat. The
clobazam aqueous solution of clobazam was more labile under exposure to visible and UV light. The bulk drug
was significantly degraded under exposure to 2 M HCl, 0.1 M NaOH or 3% H2O2. Using the tablet powder, higher
degradation rates were observed under different stress conditions. The main degradation product of clobazam
under basic condition was subsequently characterized.
Conclusion: The developed method could be used for the determination of clobazam in the presence of its
degradation products with acceptable precision and accuracy. The applicability of the proposed method was
evaluated in commercial dosage forms analysis.
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Clobazam, 7-chloro-1-methyl-5-phenyl-1, 5-benzodiazepine-
2, 4 (3H-dione) (Figure 1), is a benzodiazepine deriva-
tive which is used for the treatment of various seizure
types and epilepsy [1]. Clobazam belongs to the 1, 5-
benzodiazepine class with a pka value of 6.65. Clobazam
bulk powder is a white crystal with molecular weight of
300.7. The drug is slightly soluble in water and soluble in
alcoholic solvents. A number of HPLC methods have been
reported before for the determination of clobazam and its
metabolite in human plasma [2-6]. Also, HPLC method
has been developed for the determination of clobazam in
tablet dosage forms [7]. Clobazam is official in British* Correspondence: souri@sina.tums.ac.ir
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(USP) and an HPLC method is reported for the assay
determination of this drug in capsule dosage forms.
Literature survey showed that there is no stability indi-
cating HPLC method for the determination of clobazam
in the presence of its degradation products or its degrad-
ation behavior under stress conditions. Hence, it is im-
portant to develop an accurate, rapid and specific stability
indicating analytical method, which is suitable for routine
quality control analysis of clobazam in pharmaceutical
dosage forms. Stress testing provides important informa-
tion about the stability of the drug substance under diffe-
rent conditions. Moreover, the suitability of the proposed
analysis technique could be verified. In this study,
reversed-phase HPLC method is proposed for the deter-
mination of clobazam in bulk drug and pharmaceutical
dosage forms. The stability tests were performed underd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chemical structure of clobazam.
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rence on Harmonization (ICH) guidelines to find out the
suitability of the proposed analytical technique in the
presence of degradation products.Methods
Chemicals
The clobazam bulk powder was kindly provided by
Hakim Pharmaceutical Company (Tehran, Iran). HPLC
grade acetonitrile and analytical grade potassium dihydro-
gen phosphate were purchased from Merck (Darmastadt,
Germany). Clobazam tablets (10 mg) were from Dr Abidi
Pharmaceutical Laboratory, Tehran, Iran and obtained
from a local pharmacy.Instrumentation
The analysis was performed by using a chromatographic
system from Waters (Milford, USA) consisting of a Model
515 isocratic pump, a Model 710 plus autosampler and a
Model 480 UV–vis detector. The data processing system
was the version 1.5x of a multi-channel Chrom&Spec soft-
ware for chromatography. For heat studies, a dry air oven
(Melag, Germany) was used. A 100 W Tungsten lamp and
a low-pressure Mercury lamp 100 W were used as visible
or UV light source, respectively.
The 1H-NMR spectrum was obtained in CDCl3 using
a Bruker FT-500 Spectrometer (Bruker, Rheinstetten,
Germany). The chemical shifts (δ) relative to tetra-
methylsilane as internal standard were reported in part
per million (ppm). The mass spectrum was achieved on
an Agilent 5975C Spectrometer. The IR spectrum wasobtained by using a Nicolet 550-FT Spectrophotometer
(Nicolet, Maison, WI, USA).
Peak purity of the samples resulted from stress degrad-
ation was checked using an Agilent 1100 HPLC system
(Agilent Technologies, USA), equipped with a quater-
nary pump, an on-line degasser, an auto-sampler, a col-
umn oven, and a Photodiode Array (PDA) detector
coupled with a ChemStation Software version B.04.01
(Agilent Technologies, USA). For the peak purity ana-
lysis, the spectra were corrected for background absorp-
tion caused by the mobile phase or matrix compounds,
by subtracting the appropriate reference spectra. The
spectra were assessed in the range of 225–254 nm and
the mode of “best possible match of the entire spectrum”
was selected as the mode of normalization.
Chromatographic conditions
A Nova-pak C18 column (150 mm× 3.9 mm, 4 μm, Waters,
Milford, USA) was used for the chromatographic separ-
ation. The mobile phase was composed of 50 mM KH2PO4
(pH 8.5) and acetonitrile in the ratio of 50:50 (v/v) and
pumped at room temperature, at a flow rate of 1 ml/min.
The wavelength of the UV detector was set at 230 nm.
The mobile phase was degassed by filtration through a
0.45 μm filter and sonication for 5 min.
Stock standard solutions
A 50 μg/ml stock standard solution of clobazam was
prepared in acetonitrile. Calibration solutions of cloba-
zam at 0.1, 0.2, 0.5, 1, 2, 5, 10 and 20 μg/ml were pre-
pared by transferring various aliquots of clobazam
solution (50 μg/ml) into a series of 10 ml volumetric
flasks and completing the volume to the mark with the
mobile phase.
Linearity
Six sets of calibration standard solutions of clobazam
were prepared in mobile phase in the range of 0.1-
20 μg/ml. The solutions were analyzed according to the
optimized chromatographic conditions and the peak area
was plotted over the clobazam concentration. The statis-
tical data were calculated.
Precision and accuracy
Three different concentrations of clobazam (0.2, 2 and
20 μg/ml) within the calibration range were prepared
and analyzed in triplicate during one day and three con-
secutive days. The coefficient of variation (CV) and error
values were determined to find out the precision and
accuracy of the analytical method.
Robustness
To find out the robustness of the proposed method, the
chromatographic conditions were changed. The influence
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composition of the mobile phase were studied.
Analysis of tablets
The average weight of twenty finely powdered clobazam
tablets (10 mg) was calculated. An amount of powdered
tablet equivalent to one tablet was weighed and trans-
ferred into a 100 ml volumetric flask. After addition of
about 70 ml of water and acetonitrile (50:50, v/v), the
mixture was vortex-mixed for 15 min. The solution was
diluted to mark with the same solvent and centrifuged
at 4000 rpm for 10 min. The solution was subjected to
the analysis method after four times dilution and filtra-
tion through a 0.45 μm polypropylene syringe filter
(Teknokroma, Spain).
Recovery
The standard addition method was used to evaluate the
relative recovery of clobazam from dosage forms. Stan-
dard concentrations of clobazam were added to a solu-
tion resulted from tablet sample and analyzed. The
resulted peak area was compared with a standard solu-
tion at the same concentration level and the relative re-
covery was calculated.
Stress degradation
Acid and base induced degradation
Clobazam solutions containing 500 μg/ml in 1 M HCl,
2 M HCl and 0.1 M NaOH were allowed to stand at
room temperature or 60°C. For the HPLC analysis,Figure 2 Typical chromatograms obtained from stability studies of cl
solution in 2 M HCl after 1 h at 60°C; (c) clobazam solution in 0.1 M NaOH
1 h at 60°C; (e) clobazam solution in water after 5 days exposure to UV ligh
heat; (g) degradation product of clobazam in 0.1 M NaOH.0.5 ml of the solution was transferred into a 10 ml volu-
metric flask and the excess of acid or base were neutra-
lized with NaOH or HCl, respectively. After diluting to
the mark with the mobile phase, the solution was
injected to the HPLC system. The peak area was com-
pared with freshly prepared samples at the same initial
concentration value. The same procedure was performed
using tablet powder instead of clobazam bulk powder.
All experiments were performed in triplicate.
Hydrogen peroxide induced degradation
Clobazam solutions in 3% H2O2 (500 μg/ml) prepared
from bulk drug or tablet powder were kept at room
temperature or 60°C. After twenty times dilution with
the mobile phase, the resulted solution was injected to
the HPLC system and the peak area compared with a
standard solution at the same concentration.
Photolytic degradation
To study the effect of light on drug substance, 100 mg
of the bulk powder and also tablet powder were spread
in a watch glass and directly exposed to visible or UV-
light. The distance between the light source and the
samples was 20 cm. For HPLC analysis, 5 mg of the
powder was weighed and dissolved in 10 ml mobile
phase and injected to the HPLC system after 20 times
dilution. Clobazam solutions in water (500 μg/ml) pre-
pared from bulk powder or tablet powder was also ex-
posed to visible or UV-light. The solution was diluted in
mobile phase to give a claimed concentration of 25 μg/mlobazam. (a) clobazam standard solution (25 μg/ml); (b) clobazam
after 1 h at room temperature; (d) clobazam solution in 3% H2O2 after
t; (f) clobazam dosage form solution in water after 5 days exposure to
Table 3 Precision and accuracy of the method for





CV (%) Error (%)
Within day (n = 3)
0.200 0.199 ± 0.003 1.52 −0.50
2.000 1.977 ± 0.020 1.01 −1.15
20.000 19.967 ± 0.153 0.77 −0.17
Between day (n = 9)
0.200 0.200 ± 0.003 1.51 0.00
2.000 1.980 ± 0.021 1.04 −1.00
20.000 19.940 ± 0.092 0.46 −0.30
Table 4 The influence of small changes in mobile phase
Table 1 System suitability parameters
Parameters Found Acceptable limits
USP theoretical plates (n = 6) 4100 N > 1500
USP tailing factor (n = 6) 1.2 T < 1.5
Repeatability (tR) (n = 6) 0.48 RSD < 1%
Repeatability (peak area) (n = 6) 0.87 RSD < 1%
tR: Retention time (min); N: Theoretical plate; T: Tailing factor; RSD: Relative
Standard Deviation.
Souri et al. DARU Journal of Pharmaceutical Sciences 2014, 22:49 Page 4 of 7
http://www.darujps.com/content/22/1/49and 20 μl was injected for HPLC analysis. The percentage
of the remained clobazam was calculated using a freshly
prepared standard solution at the same concentration.
Heat degradation
To find out the thermal stability, clobazam bulk powder
and tablet powder were incubated in a dry oven at 80°C
for 5 days. Also, aqueous solutions of clobazam bulk
powder and tablet powder were incubated in a dry oven at
80°C for 5 days. Solution prepared from these samples
were injected to the HPLC system and compared with a
standard solution to calculate the percent of degradation.
Isolation of the basic degradation product of clobazam
The degradation product formed in 0.1 M NaOH after
5 h at 60°C was a white crystal. The crystals were sepa-
rated and dried in a vacuum desiccator. The purity of
this product was proved by injecting a sample solution
to the HPLC system. The retention time of the product
was about 7.5 min. The structure of this product was
elucidated by using its 1H-NMR, mass and IR spectra.
Results and discussion
Chromatographic conditions
By using a Nova-Pak C18 column and a mobile phase
consisting of 50 mM KH2PO4 (pH 8.5) and acetonitrile
(50:50, v/v), the clobazam and its degradation products
were well resolved. The representative chromatograms
(Figure 2) showed no peak interfering from excipients or
degradation products with analyte. Analysis of the sam-
ples after stress degradation studies showed that the
HPLC method is stability indicating.Table 2 Statistical data of calibration curves of clobazam
(n = 6)
Parameters Results
Linearity range 0.1-20 μg/ml
Regression equation y = 183.39 x + 22.22
Standard deviation of slope 0.89
Relative standard deviation of slope (%) 0.49
Standard deviation of intercept 2.75
Correlation coefficient (r2) 0.9997
Limit of quantification (LOQ) 0.15 μg/ml
Limit of detection (LOD) 0.05 μg/mlThe system suitability parameters (peak symmetry and
repeatability) were evaluated by six replicates injecting
of a clobazam solution (25 μg/ml) in mobile phase. The
results shown in Table 1 are within the acceptable range.Linearity
Calibration plots over the clobazam concentration range
of 0.1-20 μg/ml showed acceptable correlation coefficients.
The statistical data of the repeated calibration curves
are shown in Table 2. The limit of quantification (LOQ)
and limit of determination (LOD) were calculated ac-
cording to the following equations [8] and are presented
in Table 2.
LOQ ¼ 10σ=s and LOD ¼ 3:3σ=s
where σ is the standard deviation of intercept and s is
the slope of the calibration graph.Stability
The clobazam solutions showed acceptable stability (>99%)
relative to freshly prepared standard solutions after 7 days
in refrigerator.composition (method robustness)
Mobile phase composition Retention
time (min)
Peak area
KH2PO4 50 mM (pH 8.8)-Acetonitrile (50:50) 3.12 8063
KH2PO4 50 mM (pH 8.8)-Acetonitrile (52:48) 3.82 8078
KH2PO4 50 mM (pH 8.8)-Acetonitrile (48:52) 3.06 8178
KH2PO4 50 mM (pH 8.5)-Acetonitrile (50:50) 3.40 8117
KH2PO4 50 mM (pH 8.5)-Acetonitrile (52:48) 3.92 8087
KH2PO4 50 mM (pH 8.5)-Acetonitrile (48:52) 3.13 8147
KH2PO4 50 mM (pH 8.2)-Acetonitrile (50:50) 3.14 8205
KH2PO4 50 mM (pH 8.2)-Acetonitrile (52:48) 3.59 8180
KH2PO4 50 mM (pH 8.2)-Acetonitrile (60:52) 3.12 8107
Table 5 The results of the stress degradation tests on clobazam bulk powder using different conditions
Stress test condition Solvent Temperature Time % of clobazam Peak homogeneity
Acidic 1 M HCl Room temperature 1 h 85.2 Pass
2 M HCl Room temperature 2 days 57.8
2 M HCl 60°C 1 h 71.4
Basic 0.1 M NaOH Room temperature 1 h 64.8 Pass
0.1 M NaOH Room temperature 48 h 1.2
0.1 M NaOH 60°C 1 h 13.8
Oxidative 3% H2O2 Room temperature 48 h 75.3 Pass
3% H2O2 60°C 1 h 91.4
Photolytic
UV light Solid form Room temperature 5 days 98.1 Pass
UV light Water Room temperature 5 days 65.0
Visible light Solid form Room temperature 5 days 99.8 Pass
Visible light Water Room temperature 5 days 95.2
Heat Solid form 80°C 5 days 99.9 Pass
Water 80°C 5 days 99.8
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To find out the repeatability of the developed method,
triplicate analysis of clobazam solutions at three different
concentration levels were performed (in one day and
three consecutive days). The calculated CV (%) and er-
rors (%) values are presented in Table 3 which indicates
high precision and accuracy of the method.
Small variations in the pH value of the phosphate buf-
fer and also composition of the mobile phase did not
show significant effect on the peak area or peak shape
(Table 4) which showed the robustness of the proposed
method.
Recovery
Recovery was evaluated by the determination of the analyte
in solutions prepared by the standard addition technique.
The mean percentage recovery of 98.3 ± 0.5% was achieved.Table 6 The results of the stress degradation tests on clobaza
Stress test condition Solvent Temperature
Acidic 2 M HCl 60°C
Basic 0.1 M NaOH Room temperature
Oxidative 3% H2O2 60°C
Photolytic
UV light Solid form Room temperature
UV light Water Room temperature
Visible light Solid form Room temperature
Visible light Water Room temperature
Heat Solid form 80°C
Water 80°CDegradation studies
Acid and base induced degradation
Under acidic conditions, degradation was dependent to
the strength of hydrochloric acid and also exposure time
(Table 5). No new peak was observed in the chromato-
gram after degradation (Figure 2b). The rate of degrad-
ation of clobazam tablet powder was comparatively
higher than clobazam bulk powder under the same con-
ditions (Table 6).
In the presence of 0.1 M NaOH solution, a very fast
degradation was observed. The degradation was about
35% and 99% after 1 h or 48 h at room temperature
(Table 5). The degradation of tablet powder was more
under the same conditions (Table 6). Under basic condi-
tions, the formation of a small peak at the retention time
of 1.2 min was evident (Figure 2c). Also a white crystal
was produced which was increased by increasing them tablet powder using different conditions
Time % of clobazam Peak homogeneity
1 h 74.4 Pass
1 h 42.3 Pass
1 h 87.3 Pass
5 days 87.1 Pass
5 days 24.9
5 days 99.5 Pass
5 days 70.0
5 days 51.2 Pass
5 days 55.1
Figure 3 Chemical structure of degradation product of
clobazam in basic medium.
Souri et al. DARU Journal of Pharmaceutical Sciences 2014, 22:49 Page 6 of 7
http://www.darujps.com/content/22/1/49exposure time. After 48 h exposure time at room tem-
perature, the complete degradation of clobazam to this
product was observed.
Hydrogen peroxide induced degradation
Significant degradation of clobazam bulk powder and also
tablet powder was observed after exposure of clobazam to
hydrogen peroxide at room temperature or 60°C (Tables 5
and 6). The hydrogen peroxide peak was observed at the
retention time of about 1.2 without any other peak related
to degradation products of clobazam (Figure 2d).
Photolytic degradation
Clobazam bulk powder was relatively stable in solid state
after exposure to visible or UV-light. On the other hand,Figure 4 Mass spectrum of degradation product of clobazam in basicthe aqueous solution of clobazam bulk powder showed
significant degradation of about 5% and 35% (Table 5).
Clobazam tablet powder showed about 13% degradation
after 5 days exposure to UV light (Table 6 and Figure 2e)).
Higher degradation rates were observed for the aqueous
solution of tablet powder under visible light (30%) or UV
light (75%) after 5 Days (Table 6).
Heat degradation
Clobazam bulk powder was relatively stable under heat
after 5 days (Table 5). On the other hand, the clobazam
tablet powder and its aqueous solution were significantly
labile under heat and about 49% and 45% of degradation
was observed after 5 days exposure to 80°C (Table 6 and
Figure 2f ).
Peak purity studies
The peak purity of the samples resulted from stress deg-
radation was checked by using a photo diode array de-
tector. Peak purity results derived from the PDA
detector confirmed that the clobazam peak was homoge-
neous and pure and there is no interfering peak from
the diluents or degradation products. These results con-
firmed the stability indicating capability of the proposed
method for determination of clobazam in the presence
of its degradation products.
Characterization of the basic degradation product
According to the experimental method, the degradation
product in basic conditions was isolated. The isolated
compound was pure and showed a single peak at the
retention time of 7.5 (Figure 2g). On the basis of the
1H-NMR, mass and IR spectral data, the chemical
structure of this product was assigned as N-[4-chloro-
2-(phenyl amino) phenyl]-N-methylacetamide (Figure 3),
impurity E, which has been reported in the European
Pharmacopeia. The spectral data are as followed:
1H-NMR (CDCl3): δ (ppm); 1.93 (s, 3H, CH3-CO),
3.23 (s, 3H, NCH3), 6.84 (dd, J = 8.1 Hz and J = 2.0 Hz,medium.
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(d, J = 2.0 Hz, 1H), 7.34-7.41 (m, 2H).
Mass: m/z (%) 276 (7), 274 (21), 259 (33), 257 (100),
231 (15), 215 (18), 195 (13), 181 (7), 167 (8), 153 (7), 91
(7) (Figure 4).
IR (KBr): ν cm−1 3267 (NH), 1644 (CO).
Analysis of tablet dosage form
The active ingredient in clobazam tablets (10 mg) was
determined using the developed method. Good agree-
ment with the label claimed amount (10.29 ± 0.11 mg
per tablet) was observed with no interference from
excipeients.
Conclusion
In this study clobazam was exposed to different stress
conditions recommended in ICH guidelines. In the de-
veloped HPLC method, clobazam and its degradation
products were resolved in a single isocratic run. Cloba-
zam showed significant degradation under basic, acidic
or oxidative conditions. The bulk drug remained un-
affected under heat, UV light or visible light in the solid
form, while significant degradation in these conditions
was observed in aqueous solutions. The tablet powder
was more labile under studied degradation conditions.
The main degradation product under 0.1 M NaOH was
separated and its chemical structure was elucidated. The
proposed analytical method was relatively simple and ac-
curate and could be used for the determination of cloba-
zam in pharmaceutical dosage forms in the presence of
its degradation products.
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